Neumora Therapeutics’ (NMRA) “Buy” Rating Reiterated at HC Wainwright

Neumora Therapeutics (NASDAQ:NMRA)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research note issued on Friday,Benzinga reports. They presently have a $30.00 price objective on the stock.

A number of other research firms have also recently commented on NMRA. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price objective on shares of Neumora Therapeutics in a research report on Thursday, January 2nd. JPMorgan Chase & Co. downgraded shares of Neumora Therapeutics from an “overweight” rating to a “neutral” rating and reduced their target price for the stock from $18.00 to $15.00 in a report on Tuesday, November 5th. Royal Bank of Canada lowered shares of Neumora Therapeutics from an “outperform” rating to a “sector perform” rating and decreased their price target for the company from $29.00 to $4.00 in a research note on Thursday, January 2nd. Bank of America cut their price objective on shares of Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating for the company in a research report on Monday, January 6th. Finally, William Blair restated an “outperform” rating on shares of Neumora Therapeutics in a report on Wednesday, January 15th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, Neumora Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $16.50.

Neumora Therapeutics Stock Down 0.6 %

Shares of NASDAQ NMRA opened at $1.69 on Friday. The business’s 50 day moving average price is $5.50 and its two-hundred day moving average price is $9.83. The company has a market cap of $273.04 million, a PE ratio of -0.90 and a beta of 2.50. Neumora Therapeutics has a twelve month low of $1.60 and a twelve month high of $21.00.

Neumora Therapeutics (NASDAQ:NMRA) last issued its earnings results on Tuesday, November 12th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.06). During the same period in the prior year, the company posted ($1.14) earnings per share. As a group, research analysts anticipate that Neumora Therapeutics will post -1.61 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in NMRA. Ballentine Partners LLC acquired a new stake in shares of Neumora Therapeutics in the third quarter valued at approximately $178,000. Auour Investments LLC bought a new position in Neumora Therapeutics during the 3rd quarter worth $3,302,000. Intech Investment Management LLC acquired a new position in Neumora Therapeutics in the 3rd quarter valued at $175,000. Charles Schwab Investment Management Inc. lifted its position in shares of Neumora Therapeutics by 139.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 698,255 shares of the company’s stock valued at $9,224,000 after acquiring an additional 406,891 shares during the period. Finally, Cerity Partners LLC acquired a new stake in shares of Neumora Therapeutics during the 3rd quarter worth $3,209,000. Institutional investors and hedge funds own 47.65% of the company’s stock.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.